Importantly, in vivo evidence showing that cancer cells are addicted to mutp53 is provided by Alexandrova et al. [50], using HSP90 inhibitors; pharmacological inhibition of HSP90 by ganetespib results in degradation of mutp53 in lymphomas and prolongs survival of TP53R172H/R172H and TP53R248Q/− mice with minimal effects on TP53-null mice. The gene discussed is TP53; the disease is cancer.